These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36090909)

  • 1. Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common.
    Wentworth BJ; Caldwell SH
    Metab Target Organ Damage; 2021 Sep; 1(1):. PubMed ID: 36090909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology of nonalcoholic steatohepatitis.
    Brunt EM
    Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.
    Brunt EM
    Hepatol Commun; 2017 Jul; 1(5):370-378. PubMed ID: 29404465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial.
    Tonev D; Shumbayawonda E; Tetlow LA; Herdman L; French M; Rymell S; Thomaides-Brears H; Caseiro-Alves F; Castelo-Branco M; Ferreira C; Coenraad M; Lamb H; Beer M; Kelly M; Banerjee R; Dollinger M;
    JMIR Res Protoc; 2020 Oct; 9(10):e19189. PubMed ID: 33104014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
    Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
    Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
    [No Abstract]   [Full Text] [Related]  

  • 9. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?
    Singh SP; Barik RK
    J Clin Exp Hepatol; 2020; 10(1):88-98. PubMed ID: 32025168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician.
    Brunt EM
    Dig Dis; 2012; 30 Suppl 1():61-8. PubMed ID: 23075870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic evaluation of nonalcoholic fatty liver disease.
    Adams LA; Talwalkar JA
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S34-8. PubMed ID: 16540765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.
    Adams LA; Feldstein AE
    J Dig Dis; 2011 Feb; 12(1):10-6. PubMed ID: 21091933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Work up of fatty liver by primary care physicians, review.
    Rikhi R; Singh T; Modaresi Esfeh J
    Ann Med Surg (Lond); 2020 Feb; 50():41-48. PubMed ID: 31993196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography.
    Kim D; Kim WR; Talwalkar JA; Kim HJ; Ehman RL
    Radiology; 2013 Aug; 268(2):411-9. PubMed ID: 23564711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.
    Wieckowska A; Feldstein AE
    Semin Liver Dis; 2008 Nov; 28(4):386-95. PubMed ID: 18956295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.